Pertuzumab
Therapeutic Group
Anti-neoplasticsIndication Dosage
Pertuzumab is a medication primarily indicated for the treatment of HER2-positive breast cancer. It is typically used in combination with other HER2-targeted therapies and chemotherapy in both the neoadjuvant (before surgery) and metastatic (advanced) settings. Pertuzumab works by inhibiting HER2 protein activation, which plays a crucial role in the growth and spread of HER2-positive breast cancer cells.
Treatment Of Her2-positive Metastatic Or Locally Recurrent Unresectable Breast Cancer In Combination With Trastuzumab And Docetaxel, In Patients Who Have Not Received Previous Anti-her2 Therapy Or Chemotherapy:
By IV Infusion:
- Adults: The initial Dose Is 840mg IV infusion Over 60 Min, Followed By 420 Mg IV infusion Over 30-60 Min Every 3 Weeks.
Content
- Inj 420mg /14ml: Pertuzumab 30mg /ml Solution For Infusion Single Use Vial
Pregnancy
Positive Evidence Of Risk: Avoid
Stability
- Recombinant Humanized Monoclonal Antibody
Contra Indications
- None Known
Precautions
- None Known
Lactation
- Contraindicated. Discontinue Breast-feeding
Side Effects
- Alopecia
- Anaemia
- Arthralgia
- Chills
- Constipation
- Cough
- Decreased Appetite
- Diarrhoea
- Dizziness
- Dry Skin
- Dyspepsia
- Dyspnoea
- Febrile
- Neutropenia
- Headache
- Increased Lacrimation
- Insomnia
- Left Ventricular Dysfunction
- Leucopenia
- Malaise
- Myalgia
- Nasopharyngitis
- Oedema
- Pain
- Paronychia
- Peripheral Neuropathy
- Pleural Effusion
- Pruritus
- Pyrexia
- Rash
- Severe Hypersensitivity Reactions
- Taste Disturbance
- Nausea
- Oral Mucositis
- Vomiting
- Upper Respiratory-tract Infection.
- Rare: Interstitial Lung Disease
- Bone-marrow Suppression
- Extravasation
- Hyperuricaemia
- Thromboembolism
- Tumour Lysis Syndrome